Developer docs
API playgroundTry for free, no card

Search company profiles

Creathor Ventures

Full company profile

uuid0002bwc

Namestring
Creathor Ventures
Legal namestring
Creathor Venture Management GmbH
Websiteurl
creathor.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Creathor Ventures is a European venture capital firm founded in 1984 and headquartered in Bad Homburg, Germany, with a secondary office in Zurich/Meilen, Switzerland. The firm invests in early-stage technology-oriented companies across two primary verticals: the personalization and digitalization of healthcare, and the automation of industry. As of available data, Creathor manages €230 million across current and predecessor funds and supports an active portfolio of more than 30 companies, having financed over 220 companies historically as lead or co-lead investor.

The firm's portfolio spans biotech and gene therapy (Cube Biotech, Sirion Biotech, CEVEC Pharmaceuticals, Acousia Therapeutics), medtech (CryoTherapeutics), AI-enabled diagnostics (Blueprint Genetics), industrial IoT (EchoRing/R3 Communications), PropTech (Allthings Technologies, Wunderflats), HR/talent platforms (HeyJobs), and digital health (Humanoo). Recent exits include the sale of Cube Biotech to ArchiMed (2021), Sirion Biotech to PerkinElmer (2021), and Blueprint Genetics to Quest Diagnostics (2020), with seven billion-dollar exits and more than 20 IPOs in the firm's history.

Creathor's business model follows standard venture capital economics: management fees on committed capital (typically 1.5-2% of fund size) plus carried interest (20% above a hurdle rate) from successful exits. Deal sourcing relies primarily on direct network, referrals, and industry event participation, supplemented by content marketing through the firm's website and Medium publication ('Creathor's Corner'). The firm is led by Founder & Chairman Dr. Gert Köhler and Managing Partners Karlheinz Schmelig (Healthcare focus) and Cédric Köhler (Tech focus), whose prior experience spans McKinsey, 3i Group, Technologieholding, Herbert Quandt Group, Boehringer Mannheim, and F. Hoffmann-La Roche.

Short descriptiontext

Creathor Ventures is a European venture capital firm founded in 1984 and headquartered in Bad Homburg, Germany, investing early-stage capital in technology and healthcare companies across DACH with €230M under management.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBad Homburg, Germany
HQ citystring
Bad Homburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, early-stage investing, technology investments, healthcare venture capital, growth capital
Industry1 code
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
NAICS code2 codes
  • Other Financial Vehicles52599
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeLicensing Royalties
Description

Creathor Ventures generates revenue through traditional venture capital economics: annual management fees on committed capital (typically 1.5-2% of fund size) and carried interest (20% share of profits above the hurdle rate from successful portfolio company exits). With €230 million in funds under management and over 200 investments historically, the firm monetizes through exits including trade sales, IPOs, and strategic acquisitions of portfolio companies.

creathor.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Creathor Ventures is a venture capital firm that invests in early-stage technology and healthcare companies across the DACH region and beyond. The firm manages €230 million across its funds, providing venture capital financing, strategic guidance, and operational support to over 30 active portfolio companies. Its investment focus is on the personalization and digitalization of healthcare and the automation of industry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 7 billion dollar exits across portfolio history
+3 more records
Product overview1 text field

Creathor Ventures is a venture capital firm, not a product company. It does not offer products or services in the traditional sense. The company manages a €230 million fund (as of the source data) and provides investment financing and support to technology and healthcare companies. As a VC firm, Creathor's 'offerings' are financial investment, strategic guidance, and portfolio company support rather than technology products or SaaS platforms.

Product and service3 records
1Technology Venture Capital Investments
CategoryVenture Capital
2Healthcare Venture Capital Investments
CategoryVenture Capital
3Strategic Advisory and Portfolio Support
CategoryInvestment Advisory
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-04-18
Description

Swiss ICT Investor Club connecting investors with ICT startups. Creathor joined SICTIC to access deal flow and network within Swiss technology ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Berlin-based German early-stage investor with technology and life sciences funds; directly comparable in DACH stage, ticket size, and dual-sector thesis.

TypeDirect peer
Description

Munich-based early-stage tech VC serving German and European software and tech founders; comparable stage and geography with technology-focused thesis.

TypeDirect peer
Description

Munich-based German investment company listed on the m:access; comparable DACH mid-market tech and digital business investor with a comparable stage and sector profile.

TypeDirect peer
Description

Bavaria-focused VC arm of the Bavarian state; comparable in early-stage tech investing in the DACH region and frequently co-invests alongside Creathor and other regional funds.

TypeDirect peer
Description

Munich-based pan-European early-stage VC focused on technology, life sciences, and digital media; comparable DACH-rooted fund with healthcare specialization.

TypeDirect peer
Description

Berlin-based early-stage VC investing across European tech and health with similar DACH focus and stage; directly comparable in mandate, ticket size, and sector thesis.

TypeDirect peer
Description

Düsseldorf-based German state bank venture capital arm; co-invested with Creathor in CryoTherapeutics and CEVEC rounds and competes for similar DACH tech and healthcare deals.

TypeDirect peer
Description

Bonn-based German government-backed seed/early-stage tech investor; co-invests with Creathor on multiple portfolio companies and competes for the same early-stage DACH tech deals.

TypeDirect peer
Description

Munich-based (formerly Holtzbrinck Ventures) German VC investing across tech and healthcare from seed to growth; operates in the same DACH ecosystem with overlapping portfolio themes.

TypeDirect peer
Description

Berlin-based healthcare-focused VC; co-invested with Creathor in CryoTherapeutics and shares a healthcare transformation thesis in the DACH region.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment93 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Creathor Ventures

Venture Capitalcreathor.com

Creathor Ventures is a European venture capital firm founded in 1984 and headquartered in Bad Homburg, Germany, investing early-stage capital in technology and healthcare companies across DACH with €230M under management.

What Creathor Ventures does

Creathor Ventures is a European venture capital firm founded in 1984 and headquartered in Bad Homburg, Germany, with a secondary office in Zurich/Meilen, Switzerland. The firm invests in early-stage technology-oriented companies across two primary verticals: the personalization and digitalization of healthcare, and the automation of industry. As of available data, Creathor manages €230 million across current and predecessor funds and supports an active portfolio of more than 30 companies, having financed over 220 companies historically as lead or co-lead investor.

The firm's portfolio spans biotech and gene therapy (Cube Biotech, Sirion Biotech, CEVEC Pharmaceuticals, Acousia Therapeutics), medtech (CryoTherapeutics), AI-enabled diagnostics (Blueprint Genetics), industrial IoT (EchoRing/R3 Communications), PropTech (Allthings Technologies, Wunderflats), HR/talent platforms (HeyJobs), and digital health (Humanoo). Recent exits include the sale of Cube Biotech to ArchiMed (2021), Sirion Biotech to PerkinElmer (2021), and Blueprint Genetics to Quest Diagnostics (2020), with seven billion-dollar exits and more than 20 IPOs in the firm's history.

Creathor's business model follows standard venture capital economics: management fees on committed capital (typically 1.5-2% of fund size) plus carried interest (20% above a hurdle rate) from successful exits. Deal sourcing relies primarily on direct network, referrals, and industry event participation, supplemented by content marketing through the firm's website and Medium publication ('Creathor's Corner'). The firm is led by Founder & Chairman Dr. Gert Köhler and Managing Partners Karlheinz Schmelig (Healthcare focus) and Cédric Köhler (Tech focus), whose prior experience spans McKinsey, 3i Group, Technologieholding, Herbert Quandt Group, Boehringer Mannheim, and F. Hoffmann-La Roche.

Creathor Ventures firmographics

Firmographics
Name
Creathor Ventures
Legal name
Creathor Venture Management GmbH
Website
https://creathor.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
1–10 employees
Short description
Creathor Ventures is a European venture capital firm founded in 1984 and headquartered in Bad Homburg, Germany, investing early-stage capital in technology and healthcare companies across DACH with €230M under management.
Ownership category
akta.pro rank

Creathor Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Other Financial Vehicles (52599), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital funding
  • Early-stage investing
  • Technology investments
  • Healthcare venture capital
  • Growth capital

Where Creathor Ventures is headquartered

Location

Headquarters

HQ city
Bad Homburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Creathor Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Fund Management: Creathor Ventures generates revenue through traditional venture capital economics: annual management fees on committed capital (typically 1.5-2% of fund size) and carried interest (20% share of profits above the hurdle rate from successful portfolio company exits). With €230 million in funds under management and over 200 investments historically, the firm monetizes through exits including trade sales, IPOs, and strategic acquisitions of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Creathor Ventures product offering

Product offering

Core offering

Creathor Ventures is a venture capital firm that invests in early-stage technology and healthcare companies across the DACH region and beyond. The firm manages €230 million across its funds, providing venture capital financing, strategic guidance, and operational support to over 30 active portfolio companies. Its investment focus is on the personalization and digitalization of healthcare and the automation of industry.

Product overview

Creathor Ventures is a venture capital firm, not a product company. It does not offer products or services in the traditional sense. The company manages a €230 million fund (as of the source data) and provides investment financing and support to technology and healthcare companies. As a VC firm, Creathor's 'offerings' are financial investment, strategic guidance, and portfolio company support rather than technology products or SaaS platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Technology Venture Capital Investments
  • Healthcare Venture Capital Investments
  • Strategic Advisory and Portfolio Support

Quantifiable outcome

  • 7 billion dollar exits across portfolio history
  • +3 more outcomes

Companies that use Creathor Ventures

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Creathor Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Creathor Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SICTICminorStrategic or Co-development Partner · 18 April 2018Swiss ICT Investor Club connecting investors with ICT startups. Creathor joined SICTIC to access deal flow and network within Swiss technology ecosystem.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Creathor Ventures competitors and assessment

Company assessment

Direct peers

  • bmp Ventures: Berlin-based German early-stage investor with technology and life sciences funds; directly comparable in DACH stage, ticket size, and dual-sector thesis.
  • Target Partners: Munich-based early-stage tech VC serving German and European software and tech founders; comparable stage and geography with technology-focused thesis.
  • Mountain Alliance: Munich-based German investment company listed on the m:access; comparable DACH mid-market tech and digital business investor with a comparable stage and sector profile.
  • Bayern Kapital: Bavaria-focused VC arm of the Bavarian state; comparable in early-stage tech investing in the DACH region and frequently co-invests alongside Creathor and other regional funds.
  • Wellington Partners: Munich-based pan-European early-stage VC focused on technology, life sciences, and digital media; comparable DACH-rooted fund with healthcare specialization.
  • Earlybird Venture Capital: Berlin-based early-stage VC investing across European tech and health with similar DACH focus and stage; directly comparable in mandate, ticket size, and sector thesis.
  • NRW.BANK Venture Center: Düsseldorf-based German state bank venture capital arm; co-invested with Creathor in CryoTherapeutics and CEVEC rounds and competes for similar DACH tech and healthcare deals.
  • High-Tech Gründerfonds (HTGF): Bonn-based German government-backed seed/early-stage tech investor; co-invests with Creathor on multiple portfolio companies and competes for the same early-stage DACH tech deals.
  • HV Capital: Munich-based (formerly Holtzbrinck Ventures) German VC investing across tech and healthcare from seed to growth; operates in the same DACH ecosystem with overlapping portfolio themes.
  • Peppermint Venture Partners: Berlin-based healthcare-focused VC; co-invested with Creathor in CryoTherapeutics and shares a healthcare transformation thesis in the DACH region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Creathor Ventures social profiles

Digital presence

Creathor Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Creathor Ventures leadership team

Management profile

Number of profiles

Profiles5 records

Creathor Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Creathor Ventures M&A and investment

M&A and investment

M&A

Investments93 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creathor Ventures

What does Creathor Ventures do?

Creathor Ventures is a venture capital firm that invests in early-stage technology and healthcare companies across the DACH region and beyond. The firm manages €230 million across its funds, providing venture capital financing, strategic guidance, and operational support to over 30 active portfolio companies. Its investment focus is on the personalization and digitalization of healthcare and the automation of industry.

Is Creathor Ventures a public or private company?

Creathor Ventures is a private company. It is classified as management employee owned and is currently operating.

When was Creathor Ventures founded?

Creathor Ventures was founded in 1984. It employs 1 to 10 people.

Where is Creathor Ventures based?

Creathor Ventures is headquartered in Bad Homburg, Germany, in the Europe region.

How does Creathor Ventures make money?

One revenue line is on record: fund Management.

Who are Creathor Ventures's main competitors?

Direct peers on record are bmp Ventures, Target Partners, Mountain Alliance, Bayern Kapital, Wellington Partners, Earlybird Venture Capital, NRW.BANK Venture Center, High-Tech Gründerfonds (HTGF), HV Capital and Peppermint Venture Partners.

Does Creathor Ventures have an API?

No public API is recorded for Creathor Ventures.

What industry is Creathor Ventures in?

Creathor Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 52599 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsTacalyx Raises €11M in Seed Extension FundingTacalyx, a Berlin-based biotech, raised €11M in seed extension funding from backers including Boehringer Ingelheim Venture Fund and Eurazeo. The company will use the funds to advance TCX-201, an antibody drug conjugate against an undisclosed TACA, through preclinical development.BioSpaceTacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the ClinicTacalyx selected its first clinical candidate, TCX-201, an ADC targeting a TACA, and secured €11 million in a seed extension round. The company plans to file a clinical trial application in 2027 and expand the round with additional investors.Nordic 9Lengoo raised $20 million in a round led by Inkef Capital with existing investors Redalpine, Creathor Ventures, and TechstarsLengoo, a Berlin-based SAAS language translation provider, closed a $20 million Series B round led by Inkef Capital with existing investors. The funds will accelerate global expansion and development of its proprietary software framework. The company works with 50+ enterprise customers in Europe and the US.PR Newswirevasopharm Closes €9.5 Million Financing Roundvasopharm GmbH, a German biopharmaceutical company, announced the successful completion of a €9.5 million financing round co-led by HeidelbergCapital Private Equity and EF Investments, with participation from existing investors Bayern Kapital, Future Capital, Hanseatic Asset Management, and Ringtons Holdings, and new investor Creathor Ventures. The funding will support Chemistry, Manufacturing, and Controls (CMC) scale-up and stability testing for lead product Ronopterin (VAS203), which is in Phase III NOSTRA III trials for traumatic brain injury treatment, ahead of a potential Marketing Authorization Application filing with the European Medicines Agency. Creathor Ventures joined as a new investor and its partner Christian Leikert will join vasopharm's board of directors.FinSMEsAcousia Therapeutics Raises Close to €10M in Series B FundingAcousia Therapeutics raised close to €10M in Series B funding from LBBW Ventures, Bregua, Boehringer Ingelheim, KfW, and Creathor. The investment will advance small-molecule drug candidates, including ACOU085 for otoprotection against cisplatin-related hearing loss.startupticker.chCreathor Ventures joins SICTICCreathor Ventures, a European technology investment fund with over EUR 230 million under management, joined the Swiss ICT Investor Club (SICTIC) as a preferred co-investor. The move expands SICTIC's team to 200 angel investors and aims to help Swiss deep tech startups close larger seed funding rounds faster.FinSMEsCreathor Venture Promotes Three New PartnersCreathor Venture promoted three Investment Managers to Partners effective June 1, 2017: Christian Leikert, Dr Christian Weiss, and Christian Weniger. They join the existing management team, with Leikert focusing on life science investments and Weiss and Weniger on IT and fundraising.EU-StartupsStockholm-based Adaptive Simulations secures €1.5 million to democratize the virtual simulations marketAdaptive Simulations, a Stockholm-based deep tech startup, secured €1.5 million from Creathor Venture, Karma Ventures, and KTH Royal Institute of Technology. The company offers cloud-based automated flow simulations, with about 500,000 current users and a potential global market exceeding 10 million. The investment aims to democratize the virtual simulations market.ArcticstartupGert Köhler: The Oldest VC Guy In Europe – Off And RunningGert Köhler, the oldest active VC in Europe, founded Creathor, a venture capital firm that has invested in over 200 companies. The fund holds a portfolio of 35 startups with nearly $180 million in assets and recently sold two companies, including News Republic and Sividon.FinSMEsKnip Raises nearly €14M in Venture Capital FundingKnip, a digital insurance management platform, raised nearly €14M in venture capital funding led by Route 66 Ventures. The round included participation from Creathor, QED, and existing investors, with Pascal Bouvier joining the board. Funds will support app development, process optimization, and customer communication.